Achieve Life Sciences (ACHV) Interest Expenses (2011 - 2026)
Achieve Life Sciences (ACHV) posted Interest Expenses of $274000.0 for Q1 2026, up 1726.67% on a QoQ basis from $15000.0 in Q4 2025, and up 48.11% year-over-year from $185000.0 in Q1 2025.
Achieve Life Sciences (ACHV) Interest Expenses (2011 - 2026) Analysis & Trends
Achieve Life Sciences' Interest Expenses history runs 16 years deep, the most recent figure standing at $274000.0 for Q1 2026.
- Quarterly Interest Expenses rose 48.11% year-over-year to $274000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $672000.0 (down 80.73% YoY) and the FY2025 annual result came in at $1.4 million, down 35.78% from the prior year.
- Interest Expenses was $274000.0 for Q1 2026 at Achieve Life Sciences, up from $15000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $2.8 million in Q4 2023 and bottomed at $15000.0 in Q4 2025.
- A 5-year average of $755000.0 and a median of $481000.0 in 2022 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2022 — Interest Expenses soared 11526.67% — and 2025, when it tumbled 99.3%.
- Achieve Life Sciences' Interest Expenses stood at $1.7 million in 2022, then soared by 61.12% to $2.8 million in 2023, then retreated by 24.09% to $2.1 million in 2024, then tumbled by 99.3% to $15000.0 in 2025, then jumped by 1726.67% to $274000.0 in 2026.
- Business Quant data shows ACHV's Interest Expenses at $274000.0 in Q1 2026, $15000.0 in Q4 2025, and $192000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -42,141.15 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 100,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 32.89 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 420.30 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 28.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 1.17 Bn |
| 10 | Achieve Life Sciences | 326.16 Mn | 326.16 Mn | - | 274,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 274,000.00 |
| Mar 31, 2026 | 274,000.00 |
| Dec 31, 2025 | 15,000.00 |
| Dec 31, 2025 | 15,000.00 |
| Sep 30, 2025 | 192,000.00 |
| Sep 30, 2025 | 192,000.00 |
| Jun 30, 2025 | 191,000.00 |
| Jun 30, 2025 | 191,000.00 |
| Mar 31, 2025 | 185,000.00 |
| Mar 31, 2025 | 185,000.00 |
| Dec 31, 2024 | 2.13 Mn |
| Dec 31, 2024 | 2.13 Mn |
| Sep 30, 2024 | 366,000.00 |
| Sep 30, 2024 | 366,000.00 |
| Jun 30, 2024 | 804,000.00 |
| Jun 30, 2024 | 804,000.00 |
| Mar 31, 2024 | 813,000.00 |
| Mar 31, 2024 | 813,000.00 |
| Dec 31, 2023 | 2.81 Mn |
| Dec 31, 2023 | 2.81 Mn |